At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open Label, Randomized, Phase I/II Study of a Long Peptide Vaccine Plus TLR Agonists for Resected Stage IIb-IV Melanoma. (MEL60)
In Brief
A Phase 2 clinical trial evaluating Peptide Vaccine (LPV7) + Tetanus peptide, PolyICLC, and 2 other interventions for Melanoma and 2 related conditions. Completed, enrolled 50 participants across 2 sites.
Detailed Summary
The purpose of this study is to learn what effects (good and bad) an experimental vaccine (LPV7) plus tetanus peptide and other substances called polyICLC, resiquimod, and Montanide ISA-51 have on you and your melanoma. We will also look at whether the experimental vaccine and these drugs cause any changes in your immune system.
Study Details
Timeline
Interventions
1.5 mL administered half intradermally and half subcutaneously.
1 mL administered half intradermally and half subcutaneously
500 mg applied to vaccine site after vaccine administration
2 mL administered half intradermally and half subcutaneously